Related references
Note: Only part of the references are listed.Protein Expression and Functional Relevance of Efflux and Uptake Drug Transporters at the Blood-Brain Barrier of Human Brain and Glioblastoma
Xun Bao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort
An-Chi Tien et al.
CLINICAL CANCER RESEARCH (2019)
Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data
Jann N. Sarkaria et al.
NEURO-ONCOLOGY (2018)
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Mary E. Klein et al.
CANCER CELL (2018)
Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer
Antonella De Luca et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients
Sonya C. Tate et al.
CLINICAL PHARMACOKINETICS (2018)
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors
Birgit Geoerger et al.
CLINICAL CANCER RESEARCH (2017)
Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier
M. Bauer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Emerging targeted therapies for glioma
Julie J. Miller et al.
EXPERT OPINION ON EMERGING DRUGS (2016)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik et al.
CANCER DISCOVERY (2016)
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma
Jenny L. Pokorny et al.
CLINICAL CANCER RESEARCH (2015)
Blood-Brain Barrier: An Impediment to Neuropharmaceuticals
J. T. Henderson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors
Arijit Bhowmik et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model
Karen E. Parrish et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
Thomas J. Raub et al.
DRUG METABOLISM AND DISPOSITION (2015)
Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens
Kristen A. Batich et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells
Stacey Watkins et al.
NATURE COMMUNICATIONS (2014)
Utility of CSF in translational neuroscience
Elizabeth C. M. de Lange
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2013)
Involvement of tumor acidification in brain cancer pathophysiology
Avinash Honasoge et al.
FRONTIERS IN PHYSIOLOGY (2013)
Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
H. M. Jones et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
Paul W. Sperduto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences
Zoran Redzic
FLUIDS AND BARRIERS OF THE CNS (2011)
Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
Paul R. Lockman et al.
CLINICAL CANCER RESEARCH (2010)
Tumor pH and Its Measurement
Xiaomeng Zhang et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Sensors and regulators of intracellular pH
Joseph R. Casey et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)
Joseph W. Polli et al.
DRUG METABOLISM AND DISPOSITION (2009)
Relationship between Drug/Metabolite Exposure and Impairment of Excretory Transport Function
Maciej J. Zamek-Gliszczynski et al.
DRUG METABOLISM AND DISPOSITION (2009)
Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport
Stina Syvanen et al.
DRUG METABOLISM AND DISPOSITION (2009)
ABC Transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) Expression in the Developing Human CNS
M. Daood et al.
NEUROPEDIATRICS (2008)
On the rate and extent of drug delivery to the brain
Margareta Hammarlund-Udenaes et al.
PHARMACEUTICAL RESEARCH (2008)
Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: Establishing a treatment paradigm
Elizabeth R. Gerstner et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
Brain metastases: epidemiology and pathophysiology
IT Gavrilovic et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
Epidemiology and etiology of gliomas
H Ohgaki et al.
ACTA NEUROPATHOLOGICA (2005)
Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting - Implications of the barriers between blood and brain
ECM de Lange et al.
CLINICAL PHARMACOKINETICS (2002)
Share Paper
